Clinical effects of debulking surgery combined with neoadjuvant chemotherapy in treating ovarian cancer and its influence on tumor markers and immune function.

Objective: Exploring the clinical efficacy of tumor cell reduction combined with neoadjuvant chemotherapy in treatment of ovarian cancer. Methods: Retrospective analysis was conducted of one hundred patients with advanced ovarian cancer at Yellow River Sanmenxia Hospital from January 2017 to December 2022. They were divided into control group and observation group based on treatment methods, with 50 cases in each group. The control group was treated with tumor cell reduction surgery, the observation group treated with neoadjuvant chemotherapy and tumor cell reduction surgery. The surgical related conditions, clinical treatment effects, tumor markers, cellular immune function levels, quality of life, and adverse reactions were compared. Results: The observation group had shorter surgical and hospitalization times, with less intraoperative blood loss and abdominal fluid accumulation compared to control group (P<0.05). The serum levels in both groups of patients were significantly reduced, and observation group had a higher degree of decrease (P<0.05). The levels of cellular immune function levels in both groups improved significantly, and observation group showed more significant improvement (P<0.05). The total efficacy of observation group patients was 72.00%, higher than control group's 52.00% (P<0.05). The SS-QOL scores of both groups of patients improved significantly, and the degree of improvement in observation group was significant (P<0.05). Conclusion: The combination of tumor cell reduction surgery and neoadjuvant chemotherapy for ovarian cancer can significantly shorten surgical and hospitalization time, inhibit tumor marker expression, improve patient immune function and quality of life. [ABSTRACT FROM AUTHOR]